肌肉减少症作为外周动脉疾病预后因素:描述性综述
本描述性综述通过系统检索PubMed和Cochrane Library(2010年1月至2020年10月),纳入8项研究共1511例外周动脉疾病患者,评估肌肉减少症对预后的影响。多数研究发现骨骼肌面积减少与死亡率升高相关,但有一项研究结论相反。
要点
- 低骨骼肌面积与PAD患者死亡率升高相关。
- 肌肉密度和力量下降也与死亡率增加相关。
- 肌肉减少症可能作为PAD预后评估指标。
核心结论
- 低骨骼肌面积和质量似乎与PAD患者更高的死亡率相关。
研究设计与样本
- 系统检索PubMed和Cochrane Library数据库,检索词包括肌肉、骨骼肌、肌肉减少症、预后、住院时间、死亡、死亡率、患者再入院、外周动脉疾病、间歇性跛行和严重肢体缺血。
- 纳入2010年1月至2020年10月发表的英文、法文、西班牙文和葡萄牙文论文。
- 共纳入8篇文章,1511例患者(68.96%男性,平均年龄71.83岁)。
主要发现
- 5篇论文发现骨骼肌面积与死亡率呈负相关。
- Matsubara(2015)发现肌肉减少症患者5年总生存率较低(23.5% ± 0.18% vs 77.5% ± 0.09%,P = 0.001)。
- Matsubara(2016)报告肌肉减少症患者和无肌肉减少症患者的3年无心血管事件生存率分别为43.1%和91.2%(P < 0.01)。
- Taniguchi(2019)发现肌肉减少症患者3年总生存率为60%,无肌肉减少症患者为87%(P < 0.05)。
- Nyers(2017)结论为双侧腰大肌面积与L4椎体比值较高与死亡风险增加相关。
关键数值与推荐
- 原文未报告肌肉减少症的具体诊断标准或阈值。
临床怎么用
- 临床中可考虑评估PAD患者的骨骼肌面积、密度和力量,以辅助预后判断。
局限性
- 原文未明确报告综述的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Determine the influence of sarcopenia on the prognosis of peripheral arterial disease (PAD). METHODS: A systematic search of the PubMed and Cochrane Library databases was performed with the keywords and medical subject heading (MesH): "muscle, skeletal", "sarcopenia", "prognosis", "duration of stay", "death", "mortality", "patient readmission", "length of stay", "peripheral arterial disease", "intermittent claudication" and "critical limb ischemia". Papers published from January 2010 to October 2020 in English, French, Spanish and Portuguese were eligible for inclusion. The primary outcome was overall survival. Secondary outcomes included post-operative complications, amputation, length of hospital stay and hospital readmission. RESULTS: Of 1071 papers, 8 articles and 1511 patients were included (68.96% male, mean age 71.83 years). Five papers found an inverse relationship between SM area and mortality. Matsubara (2015) found that the 5-year overall survival rates were lower for patients with sarcopenia (23.5% ± 0.18% vs 77.5% ± 0.09% P = 0.001). Matsubara (2016) registered 3-year cardiovascular event-free survival rates of 43.1% and 91.2% for patients with and without sarcopenia (P < 0.01). Juszczak (2018) found that survival was lower in patients with reduced total psoas area. Taniguchi (2019) found that 3-year overall survival rate was 60% for patients with sarcopenia and 87% for patients without sarcopenia (P < 0.05). Shimazoe (2019) concluded sarcopenia was a significant predictor of overall survival. Distinctly, Nyers (2017) concluded that higher ratio bilateral psoas area to L4 vertebral body was associated with an increased risk of death. Two other studies analyzed other characteristics of the SM (density and strength). McDermott (2012) and found that lower calf muscle density and strength were associated with an increase in mortality. Sugai (2019) concluded that patients with major cardiovascular and limb events had a lower SM density. CONCLUSIONS: Lower SM area and mass seem to be associated with a higher mortality in PAD patients.
引用
- Ferreira JMM, Cunha P, Carneiro A, et al. Sarcopenia as a Prognostic Factor in Peripheral Arterial Disease: Descriptive Review. Ann Vasc Surg. 2021. PMID: 33556522. doi:10.1016/j.avsg.2021.01.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。